Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Lung Neoplasms 3Urogenital Neoplasms 2Leukemia 2Stomach Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Recovery 1Ovarian Neoplasms 1Metabolic Diseases 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Keratosis, Actinic 1Genital Neoplasms, Male 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Powders × Clear all
NCT04260360 2020-08-04

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

NanOlogy, LLC

Phase 1 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡